Denosumab is a fully human monoclonal antibody that specifically targets and inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key factor in the formation, function, and survival of osteoclasts, which are cells responsible for bone resorption. By inhibiting RANKL, denosumab effectively reduces bone turnover and decreases bone loss, making it a valuable therapeutic agent in conditions such as osteoporosis and certain cancers that lead to bone metastases. Denosumab is administered via subcutaneous injection and has a long half-life, allowing for less frequent dosing compared to some other treatments. Its use is associated with potential side effects, including hypocalcemia, increased risk of infections, and osteonecrosis of the jaw. As a biologic agent, denosumab is distinct from traditional small-molecule drugs, and its mechanism of action highlights the importance of targeted therapies in managing bone-related disorders. Overall, denosumab represents a significant advancement in the treatment of bone diseases, providing an effective option for patients at risk of fractures or bone complications.

Denosumab, which was approved in the United States in 2010, is a fully
human sequence IgG2 monoclonal antibody that inhibits bone resorption
by blocking the activity of receptor activator of nuclear factor-κB ligand
(RANKL). RANKL is a TNF family protein that is expressed in both
secreted and cell surface forms by a variety of bone marrow cell types
andmediates bone resorption through its receptor (RANK),which is found
on osteoclasts and osteoclast precursors . Denosumab was discovered
using XenomouseTM transgenic mice comprising human immunoglobulin
genes. The antibody is approved for treatment of postmenopausal
women with osteoporosis at high risk for fracture, and for the prevention of
skeletal-related events in patients with bone metastases from solid tumors.
Denosumab competes directly with bisphosphonates such as alendronic
acid in postmenopausal osteoporosis and with zoledronic acid in both of
these indications. It has been shown to have comparable efficacy and safety
to bisphosphonates with some tolerability and patient acceptability advantages.

Denosumab(usan)

615258-40-7: Denosumab is a fully human monoclonal antibody that specifically targets and inhibits RANKL (Receptor Activator of Nuclear Factor Kappa-Β Ligand), a key factor in the formation, function, and survival of osteoclasts, which are cells responsible for bone resorption. By inhibiting RANKL, denosumab effectively reduces bone turnover and decreases bone loss, making it a valuable therapeutic agent in conditions such as osteoporosis and certain cancers that lead to bone metastases. Denosumab is administered via subcutaneous injection and has a long half-life, allowing for less frequent dosing compared to some other treatments. Its use is associated with potential side effects, including hypocalcemia, increased risk of infections, and osteonecrosis of the jaw. As a biologic agent, denosumab is distinct from traditional small-molecule drugs, and its mechanism of action highlights the importance of targeted therapies in managing bone-related disorders. Overall, denosumab represents a significant advancement in the treatment of bone diseases, providing an effective option for patients at risk of fractures or bone complications.

Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand

Denosumab

<p>Monoclonal antibody against RANKL; anti-resorptive agent for osteoperosis treatment</p>

CAS 615258-40-7

Denosumab(usan)

Denosumab

Ref: TM-T9917

Denosumab

Ref: 3D-BD165585